Biotech | January 18, 2022
DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
The company has 47 ANDA's pending approval with the U.S.FDA
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Narayanan to lead SeQuent through next phase of consolidation and growth
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
Subscribe To Our Newsletter & Stay Updated
